ISRAPIDINE IN STAGE III CLINICAL TRIALS A... - Cure Parkinson's

Cure Parkinson's

25,480 members26,804 posts

ISRAPIDINE IN STAGE III CLINICAL TRIALS AFTER SHOWING PROMISING RESULTS IN SLOWING PD. ANYONE INVOLVED IN THESE TRIALS?

p-oui profile image
4 Replies

June 29, 2016: Phase III testing for the compound isradipine is progressing after a remarkably short recruitment period; 336 participants enrolled in less than one year. MJFF interviewed Kevin Biglan, MD, MPH, associate chair of clinical research for the Department of Neurology at the University of Rochester and co-principal investigator of STEADY-PD running the clinical trial (phase III) for Israpidine. This seems to be promising and it is an already approved drug for lowering blood pressure. It is a calcium channel blocker. It looks like (based on the interview excerpt below that it won't be approved for PD until early 2019. Assuming clinical trials continue to show positive results for slowing the disease. I wish I had gotten in on the clinical trial. Anyone out there know about the results of the clinical trials or know anyone participating in them?

MJFF: When might isradipine be approved to treat PD?

KB: The last person will be out of the study in November 2018. After that, it’ll probably be about three to six months before we have final results. That would put us into the beginning of 2019. If the results look promising, because it’s a readily available drug, it may be prescribed for Parkinson’s soon after.

MJFF: Many Parkinson’s patients who don’t have hypertension have asked if they should begin taking isradipine. Is this a good idea?

KB: At this point, we still don’t know that isradipine has beneficial effects on Parkinson’s disease, so we recommend that people don’t start taking this medication until we have more information. Also, low blood pressure is a symptom of PD, and if you don’t have hypertension, this medication may exacerbate that condition. There are other side effects, mainly dizziness and swelling, associated with isradipine, too. Certainly, before you start any medication you should talk to your physician about it. There could be something specific to you that might put you at higher risk of developing problems, so it’s not something people should start without some discussion.

michaeljfox.org/foundation/...

Written by
p-oui profile image
p-oui
To view profiles and participate in discussions please or .
Read more about...
4 Replies
laglag profile image
laglag

Thanks for posting! Sounds really promising. If we can just hold on another 2 1/2 years! In the meantime, keep fighting!

p-oui profile image
p-oui in reply to laglag

I know right?? This is an already approved drug for lowering blood pressure so if anyone has hypertension, ask for israpidine. If anyone has experience with israpidine I'd love to hear about it.

racerCP profile image
racerCP in reply to p-oui

I have been taking Isradipine and have experienced no untoward effects. I can't know whether it has slowed progression. The first week was a bit difficult with some dizziness and actually increased BP but it quickly subsided. Still waiting for study results.

Littlerody profile image
Littlerody in reply to p-oui

It is supposed to raise bp a serious problem for me. Judy

You may also like...

IPX203 shows sustained safety, efficacy in RISE-PD extension trial

who participated in the open-label extension of the RISE-PD Phase 3 trial. Final results from...

Encouraging results from the phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in PD

Cerebral NAD increase is associated with clinical improvement in Parkinson’s disease • NR induces...

List of nutrients that were tested in clinical trials with outcomes for PD 2021

Anyone involved in Buntanetap trial (AnnavisBio)? Can you share first experience?

that the trial is coming to Europe and we would participate. Does anyone involved in trial and...

Pioneering stem-cell trials in Japan report promising early results

Professor Jun Takahashi is involved in one trial expected to report results soon, in which...